Free tool
FAERS Monitor: Comtan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020796 or its brand name (Comtan, Entacapone). Reports on generic versions are filed under their own applications.
Reports
4,252
Serious
3,020
71% of reports
Hospitalization
1,451
Death reported
653
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hallucination509
- fall493
- dyskinesia491
- drug ineffective356
- death353
- parkinson^s disease289
- confusional state279
- gait disturbance273
- tremor273
- on and off phenomenon259
- somnolence208
- fatigue207
- constipation201
- dizziness199
- nausea198
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 18 |
| 2006 | 20 |
| 2007 | 31 |
| 2008 | 58 |
| 2009 | 36 |
| 2010 | 79 |
| 2011 | 68 |
| 2012 | 57 |
| 2013 | 55 |
| 2014 | 81 |
| 2015 | 105 |
| 2016 | 141 |
| 2017 | 333 |
| 2018 | 333 |
| 2019 | 375 |
| 2020 | 390 |
| 2021 | 409 |
| 2022 | 391 |
| 2023 | 277 |
| 2024 | 317 |
| 2025 | 378 |
| 2026 | 277 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,907 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| on and off phenomenonSignal | 259 | 242.0 | 214.4 | 59,054 |
| dyskinesiaSignal | 491 | 60.5 | 55.6 | 28,371 |
| hallucinationSignal | 509 | 33.6 | 31.0 | 16,030 |
| confusional stateSignal | 279 | 8.6 | 7.6 | 1,865 |
| tremorSignal | 273 | 8.1 | 7.3 | 1,716 |
| fallSignal | 493 | 7.3 | 6.8 | 2,731 |
| gait disturbanceSignal | 273 | 7.1 | 6.3 | 1,426 |
| somnolenceSignal | 208 | 5.1 | 4.5 | 690 |
| constipationSignal | 201 | 4.6 | 4.0 | 561 |
| deathSignal | 353 | 2.0 | 1.8 | 190 |
| dizziness | 199 | 2.0 | 1.7 | 97 |
| drug ineffective | 356 | 1.3 | 1.2 | 32 |
| fatigue | 207 | 1.3 | 1.2 | 16 |
| nausea | 198 | 1.2 | 1.1 | 9 |
| parkinson^s disease | 289 | 0.0 | 0.0 | 1,425,793 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.